title: Early postoperative complications of splenectomy for hematologic disease.
abstract: Splenectomy may be indicated in a variety of hematologic diseases for diagnostic reasons, therapeutic reasons, or both. Most reviews reveal a high proportion of procedures performed as part of the staging process for Hodgkin disease. Splenectomy for myelofibrosis has been associated with an increased postoperative complication rate. Other determinants of morbidity have been splenic weight and operative blood loss. The authors reviewed a series of 83 adult patients from a prospective database established in 1991 to determine the incidence of early postoperative complications associated with splenectomy for hematologic disease and to analyze patient characteristics that may predict their occurrence. Morbidity that occurred within 30 days of splenectomy was considered to be an early postoperative complication. Operative estimated blood loss and incidence of postoperative complications were correlated with patient age, preoperative platelet count, splenic weight, and diagnosis of myelofibrosis as regression covariates. Indications for splenectomy were therapeutic in 76 patients (92%). Median splenic weight was 760 g, and 22 patients had massive splenomegaly. Patients with splenic weight more than 1,500 g had a significantly higher median estimated blood loss (300 ml; p = 0.02). Splenic weight was the main determinant of estimated blood loss in a multiple linear regression analysis (p = 0.02). Twenty-two patients (27%) experienced postoperative complications and five of those patients died (6%). Patients with myelofibrosis had the highest incidence of complications (50%) and the highest postoperative mortality (21%; p = 0.04). In a logistic regression model, estimated blood loss was the only variable significantly correlated with postoperative complications (p = 0.02). Splenectomy for hematologic disease is associated with an acceptable early postoperative complication rate, even when the indication is predominantly therapeutic. Patients at particularly high risk include those with elevated operative blood loss, massive splenomegaly, and myelofibrosis.
authors: Department of Surgery, Allegheny University of the Health Sciences, Philadelphia, Pennsylvania, USA.
authors: J P
authors: JP
authors: Arnoletti
authors: J
authors: J
authors: Karam
authors: J
authors: J
authors: Brodsky
mesh_terms: D000328:Adult; D016063:Blood Loss, Surgical; D006402:Hematologic Diseases / Q000601:surgery*; D006801:Humans; D009929:Organ Size; D011183:Postoperative Complications / Q000453:epidemiology*; D055728:Primary Myelofibrosis; D012044:Regression Analysis; D012306:Risk; D013154:Spleen / Q000473:pathology; D013156:Splenectomy / Q000009:adverse effects*